Evidence map›Paper›PMID 23115234›Full record

ReviewThe Journal of biological chemistry2012

Mammalian target of rapamycin (mTOR) signaling network in skeletal myogenesis.

Yejing Ge, Jie Chen

Open access · hybridAbstract readReview
In one paragraph

Review in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 116 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Excess PrPNature communications · 2023
    Article
  16. Article
  17. Article
  18. Effect of Pinoresinol and Vanillic Acid Isolated fromMolecules (Basel, Switzerland) · 2022
    Article
  19. Role of Diet in Stem and Cancer Stem Cells.International journal of molecular sciences · 2022
    Review
  20. Self-transducible LRS-UNE-L peptide enhances muscle regeneration.Journal of cachexia, sarcopenia and muscle · 2022
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yejing GeDepartment of Cell and Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
Jie Chen
University of Illinois Urbana-Champaign · US

Funding

mTOR Signaling in Skeletal MyogenesisR01AR048914 · NIAMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI CHEN, JIE · 2003 to 2019
$4.8M
Phospholipase D signalingR01GM089771 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI CHEN, JIE · 2011 to 2025
$3.9M
NIAMS NIH HHS AR048914NIAMS NIH HHS R01 AR048914NIGMS NIH HHS GM089771NIGMS NIH HHS R01 GM089771
6 · The paper itself

Abstract

Mammalian (or mechanistic) target of rapamycin (mTOR) regulates a wide range of cellular and developmental processes by coordinating signaling responses to mitogens, nutrients, and various stresses. Over the last decade, mTOR has emerged as a master regulator of skeletal myogenesis, controlling multiple stages of the myofiber formation process. In this minireview, we present an emerging view of the signaling network underlying mTOR regulation of myogenesis, which contrasts with the well established mechanisms in the regulation of cell and muscle growth. Current questions for future studies are also highlighted.

Indexed as

AnimalsHumansMuscle DevelopmentMuscle ProteinsMuscle, SkeletalSignal TransductionTOR Serine-Threonine KinasesMTOR protein, humanMuscle ProteinsTOR Serine-Threonine Kinases

Identifiers

PMID23115234
PMCPMC3527976
OpenAlexW2087089750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.